{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinsons+Disease+With+Dementia&page=2",
    "query": {
      "condition": "Parkinsons Disease With Dementia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinsons+Disease+With+Dementia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T06:23:55.580Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02708186",
      "title": "Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia With Lewy Bodies",
        "REM Sleep Behavior Disorder",
        "Parkinson's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Nelotanserin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axovant Sciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2016-03",
      "completion_date": "2018-05",
      "has_results": true,
      "last_update_posted_date": "2020-05-20",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02708186"
    },
    {
      "nct_id": "NCT02281474",
      "title": "Nilotinib in Cognitively Impaired Parkinson Disease Patients 001",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Parkinson's Disease Dementia",
        "Diffuse Lewy Body Disease"
      ],
      "interventions": [
        {
          "name": "Nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-16",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281474"
    },
    {
      "nct_id": "NCT00178568",
      "title": "Reducing Caregiver Stress and Sleep Disturbances in Patients With Progressive Dementia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sleep Disorders"
      ],
      "interventions": [
        {
          "name": "Stress Management and Healthy Sleep Practices",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Kathy Kennedy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2003-02",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2015-05-28",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00178568"
    },
    {
      "nct_id": "NCT02640729",
      "title": "Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lewy Body Dementia",
        "Visual Hallucinations"
      ],
      "interventions": [
        {
          "name": "Nelotanserin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axovant Sciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2015-12",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2018-01-18",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 10,
      "location_summary": "Fountain Valley, California • Boca Raton, Florida • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02640729"
    },
    {
      "nct_id": "NCT07214974",
      "title": "Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Mild Cognitive Impairment (MCI)",
        "Early Stages of Cognitive Decline",
        "Alzheimer's Disease Dementia",
        "Alzheimer's Disease Diagnosis",
        "Alzheimer's Disease and Related Dementias",
        "Parkinson's Disease",
        "Parkinson's Disease (PD)",
        "Parkinson's Disease With Wearing-off Motor Fluctuations",
        "Dementia (Diagnosis)",
        "Dementia MCI (Mild Cognitive Impairment)"
      ],
      "interventions": [
        {
          "name": "Structured wellness care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Wearable brain-computer interface devices",
          "type": "DEVICE"
        },
        {
          "name": "Stem Cell Therapy - Experimental",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control - Placebo Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DEVICE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Noah Tech, Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2026-09-01",
      "completion_date": "2030-01-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 1,
      "location_summary": "Palisades Park, New Jersey",
      "locations": [
        {
          "city": "Palisades Park",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07214974"
    },
    {
      "nct_id": "NCT00056524",
      "title": "Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Stroke",
        "Parkinson's Disease",
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "AVP-923",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 600,
      "start_date": "2003-02",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Darien",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00056524"
    },
    {
      "nct_id": "NCT04369430",
      "title": "Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "AKST4290",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alkahest, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 110,
      "start_date": "2020-01-16",
      "completion_date": "2021-03-10",
      "has_results": true,
      "last_update_posted_date": "2022-10-10",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • West Bloomfield, Michigan • Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "West Bloomfield",
          "state": "Michigan"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04369430"
    },
    {
      "nct_id": "NCT00907595",
      "title": "Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Huntington's Disease",
        "Parkinson's Disease",
        "Dementia With Lewy Bodies",
        "Sleep Disorders",
        "Circadian Dysregulation"
      ],
      "interventions": [
        {
          "name": "Ramelteon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "20 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-05",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2012-11-06",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00907595"
    },
    {
      "nct_id": "NCT00623103",
      "title": "Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease Dementia"
      ],
      "interventions": [
        {
          "name": "Rivastigmine capsule",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine transdermal patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 583,
      "start_date": "2008-01",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-11-28",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Reseda",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623103"
    },
    {
      "nct_id": "NCT02871427",
      "title": "Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lewy Body Dementia",
        "Dementia With Lewy Bodies",
        "Parkinson's Disease Dementia",
        "Visual Hallucinations",
        "REM Sleep Behavior Disorder"
      ],
      "interventions": [
        {
          "name": "Nelotanserin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Axovant Sciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2016-10-20",
      "completion_date": "2019-01-17",
      "has_results": false,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-06-10T06:23:55.580Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Boca Raton, Florida + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02871427"
    }
  ]
}